|Articles|July 22, 2015

Quorum Review IRB Launches New Program for Phase I Healthy Clinical Trials

SEATTLE, WA (July 20, 2015): Quorum Review IRB, the premier central IRB, is introducing a comprehensive program that supports the unique needs of Phase I Healthy clinical trials. Quorum knows that Phase I units require immediate service and quick turnaround times. Quorum’s new program delivers.

With Quorum Review’s new Phase 1 Healthy Program, a study can be ready to enroll participants within a few days of submitting their materials. For changes mid-study, review and delivery of approval documents is even faster. Quorum’s new program also provides unprecedented alternatives in the review of recruitment materials. Quorum can conditionally approve recruitment materials before the protocol review is finalized, so you can more proactively plan for their deployment. If your group leverages generic recruitment templates and generic screening consent forms, Quorum’s new program makes using those materials easier than ever.

Quorum’s customers that have had the opportunity to preview the new Phase 1 Healthy Program proclaim it to be the “most intuitive service offering that exists for Phase 1 Healthy research.” “We know Phase I,” says Quorum’s CEO, Cami Gearhart. “We have Phase I researchers on our IRB panels and staff dedicated to supporting Phase I services. We are proud to offer our clients nimble turnaround times as well as the reliability of a large, accredited IRB.”


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.